Vanguard Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
Other funds holding AVIR
BCM
Vanguard Capital Management's AVIR Position: Q3 2026 in Review
Vanguard Capital Management reduced its Atea Pharmaceuticals (AVIR) stake by 2% in Q3 2026, selling an estimated $297K and leaving 2,906,793 shares worth $15.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2543.
Vanguard Capital Management first reported a position in AVIR in Q1 2026 and has held it in 3 quarters since. The position peaked at $17.5M in Q1 2026. 127 funds tracked by Wall St. Rank hold AVIR as of Q3 2026.
- Vanguard Capital Management held 2,906,793 shares of Atea Pharmaceuticals worth $15.1M as of Q3 2026.
- Vanguard Capital Management sold 58,069 Atea Pharmaceuticals shares in Q3 2026, an estimated $297K.
- Atea Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2543 holding.
- Vanguard Capital Management first reported a position in Atea Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Atea Pharmaceuticals position peaked at $17.5M in Q1 2026.
- 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.